Company
Innovative – Experienced – Growing.
SERDA therapeutics – a joint venture between Smith & Nephew and NLC – is a clinical-stage biopharmaceutical company developing a groundbreaking prescription product for fast and effective wound debridement.
Utilizing a proprietary proteolytic enzyme, the therapy selectively digests necrotic tissue and eschar, paving the way for wound healing while minimizing irritation. Targeting burn wounds and chronic ulcers such as diabetic foot and venous leg ulcers, SERDA’s solution addresses the challenges of current debridement methods, which are often costly, ineffective, and painful.
SERDA has completed a Phase 1 Safety and Tolerability study in July 2024. The results confirm best-in-class potential for SN514 as the protection of “periwound” skin is unlikely to be necessary in clinical use.
SERDA has initiated its Phase 1b clinical study in patients with burn wounds, a major unmet clinical need in battlefield applications and natural disasters.
This clinical development program is also supported by the US Department of Defense with a grant of $2.5 million in collaboration with the Metis Foundation, under the United States Army Medical Research Acquisition Activity (USAMRAA) under Contract No. W81XWH22C0143.